Molecular Partners Ag · SIX:MOLN
Molecular Partners — SNMMI 2025
12 slides from Molecular Partners's conference presentation, Jun 24, 2025
Slide 1: Preclinical characterization of 212Pb x MSLN Radio-DARPin Therapeutic for Ovarian Cancer
Preclinical characterization of 212Pb x MSLN Radio-DARPin 212Pb Therapeutic for Ovarian Cancer MSLN Christian Lizak, PhD SNMMI, June 24th, 2025 Contributing authors: S Wullschleger1, A Saidi2, D Buffet1, S Riesenberg1, 1. Molecular Partners AG, Zurich-Schlieren, Switzerland M Müller1, A Croset1, A
Slide 2: Disclosures
Disclosures • The presented research was funded by Molecular Partners and Orano Med • All authors are employees of Molecular Partners and Orano Med • Christian Lizak has ownership of stocks in Molecular Partners 2
Slide 3: Leverage DARPin Features to Address Biological Problems
Leverage DARPin Features to Address Biological Problems High selectivity to tumor antigens DARPin key features ✓ Small size (~15 kDa) Antibody → Deep tumor penetration → Short systemic half-life Healthy Tumor cell cell ✓ High affinity (pM range) Selectivity for membrane-bound antigen → Long tumor re
Slide 4: Radio-DARPins as Ideal Vectors for Targeted Alpha Therapy
Radio-DARPins as Ideal Vectors for Targeted Alpha Therapy Combining versatile DARPin features with the power of 212Pb MOLECULAR PARTNERS ORANO MED PIONEERS of DARPin THERAPEUTICS PIONEERS of TARGETED ALPHA THERAPY INTRINSIC DARPin PROPERTIES LINKER & 212Pb: ALPHA-EMITTING • Proven selective targetin
Slide 5: MP0712, the first 212Pb-DLL3 Targeted Radiotherapeutic for SCLC
MP0712, the first 212Pb-DLL3 Targeted Radiotherapeutic for SCLC Characteristics of MP0712 Mice xenografted IV with NCI-H82 Mice xenografted SQ with • Encouraging preclinical results NCI-H82 2000 MP0712 (4x10µCi, 1 w) o High tumor uptake “Clinical Pharmacology MP0712 (4x10µCi, 2 w) MP0712 (8x5µCi, 1
Slide 6: 212Pb x MSLN Targeted Radio-DARPin for Ovarian Cancer
212Pb x MSLN Targeted Radio-DARPin for Ovarian Cancer Overcoming biological hurdles for next-gen targeted alpha therapy Ovarian Cancer (OC): High medical need and marginal progress Product composition • 5-year OS < 50% (diagnosis often in late stage) • Limited options for 2L (platinum) resistant / r
Slide 7: Binding of Proximal DARPin is Maintained in Presence of sMSLN
Binding of Proximal DARPin is Maintained in Presence of sMSLN “Distal” DARPin Soluble MSLN sMSLN versions 296 - 597 Full length 296–597 Full-length MSLN “Proximal” DARPin 296 - 591 296–591 296 - 586 296–586 Membrane-proximal epitope 296 - 580 296–580 Tumor cell “Distal” MSLN DARPin “Proximal” MSLN D
Slide 8: Attractive BioD Profile of 212Pb x MSLN RDT Candidate
Attractive BioD Profile of 212Pb x MSLN RDT Candidate Biodistribution in hMSLN-MC38 model* • Selected binder (DARPin-2) shows favorable in vivo biodistribution: o Strong tumor uptake o Modest accumulation in healthy organs → T:K ratio of 2 (4h) and 4.5 (24h) • Data meet internal success criteria for
Slide 9: Summary & Outlook – Radio-DARPin Therapeutics
Summary & Outlook – Radio-DARPin Therapeutics ✓ Successful RDT platform optimization − Attractive biodistribution profiles (tumor, kidney, blood) ✓ MP0712: 212Pb x DLL3 RDT lead candidate for SCLC – T:K > 2 in mouse models expressing low DLL3 – Good efficacy & favorable safety profile in vivo – IND-
Slide 10: Acknowledgments
Acknowledgments Entire Team at Molecular Partners AG Orano Med Team Julien Torgue Amal Saidi Aaron Schatzmann Tania Stallons Amy Wong 10
Slide 11: Thank you for your interest!
Thank you for your interest! Molecular Partners AG Wagistrasse 14 8952 Zürich-Schlieren Switzerland www.molecularpartners.com T +41 44 755 77 00 info@molecularpartners.com
Slide 12: Disclaimer
Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, with